| Name | Title | Contact Details |
|---|
Scribe is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying cause of genetic disorders.
Nanostics is a precision health company focused on the development and commercialization of novel, non-invasive diagnostic tests for cancer and other diseases. Their core technology is an advanced liquid biopsy platform that can accurately diagnose can...
High Point Clinical Trials Center is committed to the safe and ethical conduct of clinical trials for investigational drugs in a pleasant, comfortable environment for research participants. We recognize the importance of your decision to participate in a clinical trial and strive to guide you through the process with a knowledgeable and exciting experience. Your decision of being a research participant today may benefit generations to come. Our research trials and clinical studies include research on Alzheimer`s, diabetes, overweight and healthy individuals, and encompass individuals from the Greensboro, Winston-Salem, High Point areas of North Carolina, as well as throughout the US. We offer spacious comfortable living quarters, entertainment areas (media and games rooms), catered meals and wireless internet service for our participants. High Point Clinical Trials Center offers clinical studies and trials for Greensboro, Winston Salem, High Point residents, as well as throughout the US.
Center For Innovation Inc is a Butte, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Visterra is a biotechnology company that uses its proprietary Hierotope™ Platform to identify unique disease targets and design and engineer effective therapeutics. The company`s technology is powered by computational tools and techniques, the core of which is Atomic Interaction Network (AIN) analysis, which uniquely identifies an area, or epitope, on the target site that is fundamental to its structure and function. This ideal epitope, or hierotope, becomes the target against which the company designs a novel therapeutic to effectively and durably combat the disease. The company`s lead product candidate, VIS410, is a broad spectrum human monoclonal antibody for the treatment of both seasonal and pandemic influenza, is in a phase 2a clinical trial and expected to enter a phase 2b clinical trial by year end 2017. The company`s second product candidate, VIS649, is a monoclonal antibody engineered to treat IgA nephropathy, a rare chronic kidney disease. In addition, Visterra has established a number of partnerships to progress novel antibodies engineered to treat significant diseases with limited treatment options.